Skip to main content

Table 3 Incidence of leukopenia and neutropenia per schedule according to different age intervals

From: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

 

Combination (TAC) schedule (n = 450)

Sequence schedule (n = 360)

Combination dose-dense (ATdd) schedule (n = 121)

Sequence dose-dense schedule (n = 86)

  

Nontaxane

Taxane

 

Nontaxane (dose-dense epirubicin)

Taxane (dose-dense paclitaxel)

Leukopenia

      

   Patients aged < 60 years

878 (57.3)

423 (43.4)

419 (47.3)

164 (50.2)

82 (29.2)

7 (2.6)

   Patients aged 60 to 64 years

175 (65.3)

124 (53.9)

107 (51.0)

49 (61.3)

20 (36.4)

0 (0.0)

   Patients aged > 64 years

111 (64.9)

99 (60.7)

71 (49.0)

25 (62.5)

17 (42.5)

1 (2.9)

Neutropenia

      

   Patients aged < 60 years

371 (37.5)

455 (52.8)

346 (45.3)

136 (43.5)

74 (29.7)

20 (8.7)

   Patients aged 60 to 64 years

139 (56.7)

106 (52.0)

79 (44.1)

37 (47.4)

18 (36.7)

2 (5.0)

   Patients aged > 64 years

91 (55.2)

97 (65.5)

61 (48.4)

17 (43.6)

11 (33.3)

1 (3.2)

Febrile neutropenia

      

   Patients aged < 60 years

140 (9.3)

9 (1.0)

19 (2.5)

14 (4.5)

0 (0.0)

0 (0.0)

   Patients aged 60 to 64 years

30 (11.3)

1 (0.5)

5 (2.8)

4 (5.1)

3 (6.4)

0 (0.0)

   Patients aged > 64 years

24 (14.3)

2 (1.4)

1 (0.8)

2 (5.1)

0 (0.0)

0 (0.0)

  1. Data presented as n (%). All percentage values are valid. TAC, docetaxel/doxorubicin/cyclophosphamide; ATdd, doxorubicin/docetaxel dose-dense.